SPI 339

Drug Profile

SPI 339

Alternative Names: NEO 339

Latest Information Update: 02 Jul 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spectrum Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Mild cognitive impairment

Most Recent Events

  • 02 Jul 2003 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
  • 02 Jul 2003 Discontinued - Preclinical for Mild cognitive impairment in USA (unspecified route)
  • 02 Jul 2003 SPI 339 is available for licensing (http://www.spectrumpharm.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top